Furen's acquisition of prescription drugs may usher in a dramatic change

Furen Pharmaceuticals intends to purchase a total of 100% of the prescription group held by 14 trading parties, including majority shareholder Furen Group, by issuing shares and paying cash. Data show that the pharmaceutical group is a chemical, traditional Chinese medicine and raw materials research and development, production and sales in one of the modern large-scale pharmaceutical groups, not only the core pharmaceutical companies under the Furen Group, but also the furen Group subsidiaries in the largest and most effective pharmaceutical products production enterprises.
Total assets from 1.3 billion yuan to 9.2 billion yuan, operating income from 300 million yuan to 3.7 billion yuan, net profit from 11 million yuan to 500 million yuan, Furen Pharmaceuticals is about to face a dramatic change.
November 13, Furen Pharmaceuticals announced that it intends to purchase a total of 100% of the prescription group held by 14 trading parties, including majority shareholder Furen Group, by issuing shares and paying cash. And to no more than 10 qualified specific objects of non-public issue of shares supporting the raising of funds, the total amount does not exceed 5.3 billion yuan.
this time, the corresponding price-earnings ratio of the asset appraisal price of the drug-making group is 12.95 and the price-to-earnings ratio is 2.47, which is lower than the average of the comparable trading cases and protects the interests of the original investors of the listed company.
data show that the pharmaceutical group is a chemical, traditional Chinese medicine and raw materials research and development, production and sales in one of the modern large-scale pharmaceutical groups, not only the core pharmaceutical companies under the Furen Group, but also the largest and most effective subsidiaries of the Furen Group pharmaceutical products production enterprises.
Through years of research accumulation and business development, the pharmaceutical group has developed into a variety of comprehensive pharmaceutical enterprises, in the pharmaceutical industry has a strong comprehensive strength and market competitiveness, brand advantages, regional resource advantages are more obvious.
, the pharmaceutical group has more than 480 drug approval numbers, including more than 300 varieties selected in the Health Insurance Directory (2017 edition). With the promotion of the new national medical reform, the rich product range of the pharmaceutical group can better adapt to the future market trends of drug sales.
At the same time, the pharmaceutical group attaches great importance to research and development work, in line with the principle of production generation, research generation, reserve generation, and actively develop and develop new products in line with market demand, high scientific and technological content, high added value, has formed a "company research and development as the core, jointly with other first-class pharmaceutical research institutions as the carrier" of scientific research and development system, the proportion of new drug research and development investment increased year by year.
the size and profitability of the pharmaceutical group has obviously surpassed that of listed companies. As of December 31, 2016, the total assets of the pharmaceutical group and listed companies were RMB7,515 million and RMB1,273 million, respectively, and the owner's equity attributable to shareholders of the parent company was RMB3,852 million and RMB369 million, respectively. In fiscal 2016, the operating income of the pharmaceutical group and listed companies was RMB4,534 million and RMB496 million, respectively, and the net profit attributable to shareholders of the parent company was RMB653 million and RMB17.6567 million, respectively.
So, from the protection of investors' interests, subject to the small scale, single-product listed companies in the development of Chinese medicine business speed into a bottleneck, sales scale and operating performance in the short term difficult to further improve, inject new performance growth momentum has been inevitable, the future development of listed companies and the protection of the interests of investors will be a great benefit.
, the basic realization of the furen Group's core pharmaceutical assets listed as a whole. Through this transaction, the listed company intends to acquire the pharmaceutical group owned by Furen Group, and intends to acquire the biopharmaceutical research and development company owned by Furen Group through the pharmaceutical group, to build the company into a large-scale integrated pharmaceutical listed company platform covering chemical drugs, traditional Chinese medicine, API, biopharmaceuticals, and basically realize the overall listing of Furen Group's core pharmaceutical assets. After the completion of this transaction, the company will achieve unified planning, unified management, unified operation of intensive operations in the field of medicine, the scale advantage will be further revealed.
, significantly enhance the profitability of listed companies. Through this transaction, the investment of pharmaceutical assets with strong profitability will greatly enhance the company's operating scale and profitability level, improve its financial position, significantly enhance its sustained profitability, effectively improve asset quality and risk resistance, in line with the interests of listed companies and all shareholders.
in accordance with its performance commitments, the net profit achieved by the Pharmaceutical Group in 2017, 2018 and 2019 will be no less than 736 million yuan, 808 million yuan and 874 million yuan, respectively. After the completion of the transaction, the profitability of listed companies will achieve a huge leap into the pharmaceutical listed companies in the forefront of profitability.
again, it is conducive to avoiding competition between the industry. After the completion of this transaction, the main core high-quality pharmaceutical assets of Furen Group have been injected into listed companies, listed companies and Furen Group in the pharmaceutical business competition issues will be significantly reduced. At the same time, in order to avoid competition between the controlling shareholders and the actual controllers of the listed company, clear and practical measures and time plans have been put forward to protect the interests of the listed company from loss.
, it also enhances risk resistance and expands the space for future growth. After the completion of this transaction, the main business of listed companies from a relatively single Traditional Chinese medicine business to a comprehensive pharmaceutical business, will significantly enhance the listed company's ability to resist risks, expand the future development space. At the same time, the injection of listed companies can use the capital market platform to broaden financing channels, further enhance corporate visibility and brand influence, enhance core competitiveness, is conducive to the realization of the interests of listed companies to maximize the interests of shareholders. (Hexun.com)